Bio
Andrew joined ORNL in 2022 and is currently a member the Configuration Management & CAD Support team as part of the Technical Support Services Group; supporting the Enrichment Science and Engineering Division within the Isotope Science and Engineering Directorate. He has over 16 years experience in mechanical design, 3D modeling, and research and development.
Additional areas of focus include Solidworks PDM administration, 3D printing, new product testing, and documentation and control within an ISO9001 environment.
Professional Experience
Oak Ridge National Laboratory; June 2022 - Present
- Configuration Management & CAD Support - Technical Support Services; December 2023 - Present
- Mechanical Designer - Testbed Design Engineering; June 2022 - November 2023
Best ABT (ABT Molecular Imaging); August 2014 - June 2022
- Senior Mechanical Designer - Research and Development; July 2018 - June 2022
- PDM Administrator - Research and Development; October 2015 - June 2022
- Mechanical Designer - Research and Development; August 2014 - July 2018
Education
Pellissippi State Community College
- Associate of Applied Science in Mechanical Engineering Technology
Trademarks and Patents
Dose Synthesis Card for Use with Automated Biomarker Production System
US US 20150157743 A1 · Filed Feb 10, 2015
- Microfluidic radiopharmaceutical production system and process for synthesizing per run approximately, but not less than, ten (10) unit doses of radiopharmaceutical biomarker for use in positron emission tomography (PET). A radioisotope from an accelerator or other radioisotope generator is introduced into a reaction vessel, along with organic and aqueous reagents, and the mixture heated to synthesize a solution of a pre-selected radiopharmaceutical. The solution is purified by passing through a combination of solid phase extraction purification components, trap and release components, and a filter. The synthesis process reduces waste and allows for production of biomarker radiopharmaceuticals on site and close to the location where the unit dose will be administered to the patient. On-site, as-needed production of radiopharmaceuticals in small doses reduces the time between synthesis of the radiopharmaceutical and administration of that radiopharmaceutical, minimizing loss of active isotopes through decay and allowing production of lesser amounts of radioisotopes overall.